R3 Dynamic Duo

🔬 R3 — Research Peptide

R3 (LY 3437943) is an investigational research peptide and a triple-agonist that activates the GLP-1, GIP, and glucagon (GCG) receptors. It is studied for its potential effects on weight management, metabolic regulation, and energy balance in preclinical and clinical research settings.

Research Focus & Mechanism

• GLP-1 receptor activation: Investigated for improving glycemic control and regulating appetite

• GIP receptor activation: Studied for enhancing insulin secretion and supporting glucose metabolism

• Glucagon receptor activation: Explored for increasing energy expenditure, lipolysis, and potential effects on liver fat metabolism

• Slows gastric emptying and reduces caloric intake in research models, contributing to weight reduction studies

Research Insights

• Phase 2 trials in humans have shown significant body-weight reduction in obesity research models (up to ~24% over 48 weeks in highest dose groups)

• Explored for potential improvements in blood glucose, lipid profiles, and metabolic biomarkers

• Being investigated in combination or comparison studies with other peptides for enhanced efficacy in weight and metabolic research

🔍 Cagrilintide — Research Peptide

Cagrilintide is a synthetic research peptide and a long acting analogue of the hormone amylin. It has been developed to investigate pathways of appetite, satiety, energy balance, and metabolic regulation.

Research Focus & Mechanism

• It mimics endogenous amylin (islet amyloid polypeptide), which is secreted by pancreatic β cells along with insulin and plays a role in regulating food intake and gastric emptying. 

• Cagrilintide is modified for extended half life (due to fatty acid chain linking etc) so that it can serve in once weekly dosing models in research. 

• Through activation of the amylin receptor (and via cross activation of calcitonin receptors) it is studied for:

o increasing satiety / reducing appetite

o slowing gastric emptying

o influencing caloric intake, energy expenditure, and weight/fat mass in metabolic models

o potential synergy with GLP 1 receptor agonists in weight management research.

⚠️ Disclaimer:

R3 and CAG are intended for laboratory research purposes only.

It is not approved for human use, consumption, or medical treatment.